Cargando…

Mutated KRAS Is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy

Background. The main attention regarding prognostic and predictive markers in NSCLC directs towards the EGFR-targeted pathway, where the most studied genetic alterations include EGFR mutations, EGFR copy number, and KRAS mutations. We wanted to explore the prognostic impact of mutated KRAS in the st...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hallqvist, A., Enlund, F., Andersson, C., Sjögren, H., Hussein, A., Holmberg, E., Nyman, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4437400/ https://www.ncbi.nlm.nih.gov/pubmed/26316935 http://dx.doi.org/10.1155/2012/587424

Ejemplares similares

Adverse events reporting in stage III NSCLC trials investigating surgery and radiotherapy
por: Iseli, Thomas, et al.
Publicado: (2020)

Prognostic Implication of KRAS G12C Mutation in a Real-World KRAS-Mutated Stage IV NSCLC Cohort Treated With Immunotherapy in The Netherlands
por: Noordhof, Anneloes L., et al.
Publicado: (2023)

The Independent Prognostic Effect of Lymph Node Dissection on Patients With Stage IA NSCLC With Different T Stages
por: Zhao, Dechang, et al.
Publicado: (2021)

Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
por: Fitzpatrick, Orla, et al.
Publicado: (2021)

KRAS in NSCLC: State of the Art and Future Perspectives
por: Cascetta, Priscilla, et al.
Publicado: (2022)

KRAS Mutations Impact Clinical Outcome in Metastatic Non-Small Cell Lung Cancer
por: Eklund, Ella A., et al.
Publicado: (2022)

Prognostic impact of CD34 and SMA in cancer‐associated fibroblasts in stage I–III NSCLC
por: Schulze, Arik Bernard, et al.
Publicado: (2019)

Treatment-duration is related to changes in peripheral lymphocyte counts during definitive radiotherapy for unresectable stage III NSCLC
por: Zhao, Qianqian, et al.
Publicado: (2019)

Gross Tumor Volume Segmentation for Stage III NSCLC Radiotherapy Using 3D ResSE-Unet
por: Yu, Xinhao, et al.
Publicado: (2022)

The current treatment landscape in the UK for stage III NSCLC
por: Evison, Matthew
Publicado: (2020)

Clinical Stage III NSCLC Patients Treated with Neoadjuvant Therapy and Surgery: The Prognostic Role of Nodal Characteristics †
por: Chiappetta, Marco, et al.
Publicado: (2022)

Implications of KRAS mutations in acquired resistance to treatment in NSCLC
por: Del Re, Marzia, et al.
Publicado: (2017)

Prognostic Value of Radiotherapy and Chemotherapy in Stage I–III Merkel Cell Carcinoma
por: Bi, Aihong, et al.
Publicado: (2022)

Voxel-Level BED Corrected Dosimetric and Radiobiological Assessment of 2 Kinds of Hybrid Radiotherapy Planning Methods for Stage III NSCLC
por: Wang, Hao, et al.
Publicado: (2022)

Prognostic factors of survival in stage IV colorectal cancer with synchronous liver metastasis: Negative effect of the KRAS mutation
por: Díez-Alonso, Manuel, et al.
Publicado: (2021)

Treating KRAS-mutant NSCLC: latest evidence and clinical consequences
por: Garrido, Pilar, et al.
Publicado: (2017)

A Radiogenomics Ensemble to Predict EGFR and KRAS Mutations in NSCLC
por: Moreno, Silvia, et al.
Publicado: (2021)

The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC
por: Weidhaas, Joanne B., et al.
Publicado: (2023)

Independent prognostic value of fascin immunoreactivity in stage III–IV colonic adenocarcinoma
por: Puppa, G, et al.
Publicado: (2007)

Lymph Node Ratio: Is It an Independent Prognostic Factor for Stage III Cutaneous Melanoma?
por: Salari, Abolfazl, et al.
Publicado: (2018)

Update on the Management of Stage III NSCLC: Navigating a Complex and Heterogeneous Stage of Disease
por: Sathiyapalan, Arani, et al.
Publicado: (2023)

Abemaciclib in Combination With Pembrolizumab for Stage IV KRAS-Mutant or Squamous NSCLC: A Phase 1b Study
por: Pujol, Jean-Louis, et al.
Publicado: (2021)

High-dose concurrent chemo–proton therapy for Stage III NSCLC: preliminary results of a Phase II study
por: Oshiro, Yoshiko, et al.
Publicado: (2014)

Evaluate the outcome of pneumonectomy for stage III a-N2 NSCLC
por: Park, Sungjoon, et al.
Publicado: (2015)

Neoadjuvant Immuno-Chemotherapy: A New Perspective for Stage III NSCLC?
por: Yao, Yuanshan, et al.
Publicado: (2022)

Protocol for the isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): a feasibility study
por: Haslett, Kate, et al.
Publicado: (2016)

Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX
por: Park, Hye Eun, et al.
Publicado: (2021)

Kras mutations increase telomerase activity and targeting telomerase is a promising therapeutic strategy for Kras-mutant NSCLC
por: Liu, Weiran, et al.
Publicado: (2016)

BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC
por: Jauset, Toni, et al.
Publicado: (2018)

KRAS G12C Mutations in NSCLC: From Target to Resistance
por: Addeo, Alfredo, et al.
Publicado: (2021)

Adagrasib: A landmark in the KRAS(G12C)‐mutated NSCLC
por: Tian, He, et al.
Publicado: (2022)

Post-operative radiotherapy in NSCLC.
por: Stewart, L., et al.
Publicado: (1997)

Prognostic Significance of the Loss of Heterozygosity of KRAS in Early-Stage Lung Adenocarcinoma
por: Khadse, Anand, et al.
Publicado: (2022)

Correction: Protocol for the isotoxic intensity modulated radiotherapy (IMRT) in stage III non-small cell lung cancer (NSCLC): a feasibility study
Publicado: (2016)

Patterns of nodal spread in stage III NSCLC: importance of EBUS-TBNA and (18)F-FDG PET/CT for radiotherapy target volume definition
por: Guberina, Maja, et al.
Publicado: (2021)

Impact of microvessel patterns and immune status in NSCLC: a non-angiogenic vasculature is an independent negative prognostic factor in lung adenocarcinoma
por: Paulsen, Erna-Elise, et al.
Publicado: (2023)

Tracheo-parenchymal fistula following concurrent chemo-radiation for stage III NSCLC
por: Alzghoul, Bashar, et al.
Publicado: (2016)

Pneumonitis During Durvalumab Consolidation Therapy Affects Survival in Stage III NSCLC
por: Kinehara, Yuhei, et al.
Publicado: (2023)

Real-World Journey of Unresectable Stage III NSCLC Patients: Current Dilemmas for Disease Staging and Treatment
por: Agbarya, Abed, et al.
Publicado: (2022)

Exploration and validation of radiomics signature as an independent prognostic biomarker in stage III-IVb nasopharyngeal carcinoma
por: Ouyang, Fu-Sheng, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_qe2eg6soveqm4dgsos0i1vrv27